🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to health experts.

A Global Challenge

The sexually transmitted infection are increasing worldwide, with data suggesting in excess of 82 million instances annually. Notably increased rates are reported in Africa and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted available drugs presently on offer.”

Medical experts are deeply concerned about the rise in drug-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Secure Approval

Zoliflodacin, marketed under the name a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Scientists hope that specific application of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in the same week. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the pharmaceutical company Innoviva to see it through.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

Based on findings detailed in a major medical journal, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the typical regimen, which involves a dual-drug approach. The study involved nearly 1,000 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the rights to license and sell the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have shared positive views. Access to a easy-to-administer therapy of this kind is described as a "critical tool" for public health efforts. This is viewed as essential to reduce the burden of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea globally.